Used in targeted cancer therapy, particularly for inducing apoptosis in tumor cells expressing TRAILR2. This antibody binds specifically to the death receptor TRAILR2, activating the extrinsic apoptotic pathway in cancer cells while sparing normal cells, making it a promising agent in oncology. It is being investigated in clinical trials for solid tumors and hematological malignancies. Its high specificity allows integration into antibody-drug conjugates or combination regimens with chemotherapy and immune checkpoint inhibitors to enhance anti-tumor efficacy.